Patents by Inventor Arnold J. Gutierrez
Arnold J. Gutierrez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8653248Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.Type: GrantFiled: June 13, 2002Date of Patent: February 18, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
-
Patent number: 7057027Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: GrantFiled: December 8, 2003Date of Patent: June 6, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Patent number: 6962783Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: GrantFiled: December 18, 2001Date of Patent: November 8, 2005Assignee: Isis Pharmaceuticals, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Patent number: 6875593Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: GrantFiled: November 14, 2002Date of Patent: April 5, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Publication number: 20040265802Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: ApplicationFiled: November 14, 2002Publication date: December 30, 2004Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Publication number: 20040220395Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: ApplicationFiled: December 8, 2003Publication date: November 4, 2004Applicant: Isis Pharmaceuticals, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Publication number: 20030170680Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: ApplicationFiled: November 14, 2002Publication date: September 11, 2003Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Publication number: 20030120065Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.Type: ApplicationFiled: June 13, 2002Publication date: June 26, 2003Applicant: Isis Pharmaceuticals, Inc.Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
-
Publication number: 20030096980Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: ApplicationFiled: December 18, 2001Publication date: May 22, 2003Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Patent number: 6495672Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.Type: GrantFiled: November 21, 2000Date of Patent: December 17, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
-
Patent number: 6465649Abstract: Disclosed are methods for the dealkylation of phosphonate esters by use of trimethylchlorosilane as the dealkylating agent. In particular, this invention is directed to the discovery that high yields for the dealkylation of phosphonate esters can be achieved within relatively short reaction times by the use of trimethylchlorosilane provided that the dealkylation procedure occurs in a sealed vessel containing a compatible solvent.Type: GrantFiled: August 17, 2000Date of Patent: October 15, 2002Assignee: Gilead Sciences, Inc.Inventors: Arnold J. Gutierrez, Ernest J. Prisbe, John C. Rohloff
-
Patent number: 6447998Abstract: The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.Type: GrantFiled: August 5, 1997Date of Patent: September 10, 2002Assignee: Isis Pharmaceuticals, Inc.Inventors: Brian C. Froehler, Arnold J. Gutierrez, Mark D. Matteucci
-
Patent number: 6380368Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: GrantFiled: February 12, 1996Date of Patent: April 30, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Mattencci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Patent number: 5830653Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be incorporated into pharmaceutically acceptable carriers and can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Assignee: Gilead Sciences, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo
-
Patent number: 5645985Abstract: Novel oligomers are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiological pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compositions of the invention can be used used for diagnostic purposes in order to detect viruses or disease conditions.Type: GrantFiled: November 25, 1992Date of Patent: July 8, 1997Assignee: Gilead Sciences, Inc.Inventors: Brian Froehler, Rick Wagner, Mark Matteucci, Robert J. Jones, Arnold J. Gutierrez, Jeff Pudlo